Ablation of EWS-FLI1 by USP9X inhibition suppresses cancer cell growth in Ewing sarcoma
The neomorphic transcription factor EWS-FLI1 is a key driver of Ewing sarcoma. Ablation of EWS-FLI1 may present a promising therapeutic strategy for this malignancy. Here we found that the deubiquitinase, ubiquitin specific peptidase 9 X-linked (USP9X) stabilizes EWS-FLI1 protein expression in Ewing...
Saved in:
Published in | Cancer letters Vol. 552; p. 215984 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
Ireland
Elsevier B.V
01.01.2023
Elsevier Limited |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | The neomorphic transcription factor EWS-FLI1 is a key driver of Ewing sarcoma. Ablation of EWS-FLI1 may present a promising therapeutic strategy for this malignancy. Here we found that the deubiquitinase, ubiquitin specific peptidase 9 X-linked (USP9X) stabilizes EWS-FLI1 protein expression in Ewing sarcoma. We show that USP9X binds the ETS domain of EWS-FLI1 in Ewing sarcoma cells and deubiquitinates EWS-FLI1 and that USP9X and EWS-FLI1 protein expression is correlated in clinical Ewing sarcoma specimens. We found that treatment of Ewing sarcoma cells with the USP9X inhibitor WP1130 mediates rapid EWS-FLI1 degradation in vitro and in vivo which coincides with reduced growth of Ewing sarcoma cells and tumors. Our results suggest that USP9X might be a potential therapeutic target to mediate EWS-FLI1 depletion in Ewing sarcoma.
•USP9X interacts with EWS-FLI1 through the ETS domain.•USP9X deubiquitinates and stabilizes EWS-FLI1.•USP9X inhibition by WP1130 could reduce cell proliferation of Ewing sarcoma.•USP9X loss and inhibition affects migration of Ewing sarcoma cells. |
---|---|
ISSN: | 0304-3835 1872-7980 |
DOI: | 10.1016/j.canlet.2022.215984 |